CG Oncology Financial Statements
NASDAQ: CGONHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 63.82 0.00%
CG Oncology revenue and earnings
In fiscal 2025, CG Oncology generated $4.0 million in revenue, up 254.7% from fiscal 2024, its 2nd consecutive year of revenue growth. CG Oncology reported a net loss of $161.0 million, compared with a loss of $88.0 million a year earlier. Operating margin was -4722.1%.
Diluted earnings per share came in at -$2.08. Over the last 2 fiscal years, CGON's revenue has grown at a 345.0% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
CG Oncology income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Revenue | 4.04M | 1.14M | 204.00K |
| Revenue growth (YoY) | +254.70% | +458.33% | — |
| Operating Expenses | — | 115.81M | 55.65M |
| Research & Development | 116.64M | 82.10M | 45.75M |
| Operating Income | -190.77M | -114.67M | -55.45M |
| Other Income (Expense) | 29.78M | 26.63M | 6.84M |
| Income Tax | -270.00K | 1.00K | 1.00K |
| Net Income | -161.00M | -88.04M | -48.61M |
| Net Income growth (YoY) | — | — | — |
| EPS (Basic) | -2.08 | -1.41 | -15.65 |
| EPS (Diluted) | -2.08 | -1.41 | -15.65 |
| Shares Outstanding (Basic) | 77.30M | 62.50M | 4.33M |
| Shares Outstanding (Diluted) | 77.30M | 62.50M | 4.33M |
| EBITDA | -189.33M | -114.63M | -55.43M |
| Operating Margin | -4722.13% | -10067.25% | -27180.88% |
| Net Margin | -3985.02% | -7729.50% | -23826.96% |
This table shows 3 annual periods of CG Oncology's income statement, from FY 2025 back to FY 2023, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow CGON's reporting calendar. What is a income statement?